open access

Vol 13, No 5 (2018)
Heart failure
Published online: 2018-09-14
Get Citation

The impact of sacubitril/valsartan on functional mitral regurgitation in HFrEF

Joanna Berner, Małgorzata Lelonek
DOI: 10.5603/FC.a2018.0077
·
Folia Cardiologica 2018;13(5):474-480.

open access

Vol 13, No 5 (2018)
Heart failure
Published online: 2018-09-14

Abstract

In the drug therapy of a 65-year-old male with chronic heart failure with reduced ejection fraction, New York Heart Association class III, with numerous co-morbidities including severe functional mitral regurgitation (FMR), in accordance
with the 2016 European Society of Cardiology guidelines, angiotensin receptor blocker was replaced with sacubitril/
/valsartan. During further ambulatory observation, significantly reduced FMR was noted. This case report presents
the current state of knowledge regarding the broad benefits of using sacubitril/valsartan in everyday clinical practice.

Abstract

In the drug therapy of a 65-year-old male with chronic heart failure with reduced ejection fraction, New York Heart Association class III, with numerous co-morbidities including severe functional mitral regurgitation (FMR), in accordance
with the 2016 European Society of Cardiology guidelines, angiotensin receptor blocker was replaced with sacubitril/
/valsartan. During further ambulatory observation, significantly reduced FMR was noted. This case report presents
the current state of knowledge regarding the broad benefits of using sacubitril/valsartan in everyday clinical practice.

Get Citation

Keywords

heart failure with reduced ejection fraction, sacubitril/valsartan, functional mitral regurgitation

About this article
Title

The impact of sacubitril/valsartan on functional mitral regurgitation in HFrEF

Journal

Folia Cardiologica

Issue

Vol 13, No 5 (2018)

Pages

474-480

Published online

2018-09-14

DOI

10.5603/FC.a2018.0077

Bibliographic record

Folia Cardiologica 2018;13(5):474-480.

Keywords

heart failure with reduced ejection fraction
sacubitril/valsartan
functional mitral regurgitation

Authors

Joanna Berner
Małgorzata Lelonek

References (28)
  1. Ponikowski P, Voors AA, Anker SD, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27): 2129–2200.
  2. Rywik TM, Kołodziej P, Targoński R, et al. Characteristics of the heart failure population in Poland: ZOPAN, a multicentre national programme. Kardiol Pol. 2011; 69(1): 24–31.
  3. Rywik TM, Zieliński T, Piotrowski W, et al. Heart failure patients from hospital settings in Poland: population characteristics and treatment patterns, a multicenter retrospective study. Cardiol J. 2008; 15(2): 169–180.
  4. Balsam P, Tymińska A, Kapłon-Cieślicka A, et al. Predictors of one-year outcome in patients hospitalized for heart failure: results from the Polish part of the Heart Failure Pilot Survey of the European Society of Cardiology. Kardiol Pol. 2016; 74(1): 9–17.
  5. Czech M, Opolski G, Zdrojewski T, et al. The costs of heart failure in Poland from the public payer's perspective. Polish programme assessing diagnostic procedures, treatment and costs in patients with heart failure in randomly selected outpatient clinics and hospitals at different levels of care: POLKARD. Kardiol Pol. 2013; 71(3): 224–232.
  6. Niewydolność serca w Polsce — raport 2016. Materiały informacyjne Sekcji Niewydolności Serca Polskiego Towarzystwa Kardiologicznego (PTK) Warszawa, 2016.
  7. Kajimoto K, Sato N, Takano T, et al. investigators of the Acute Decompensated Heart Failure Syndromes (ATTEND) registry. Functional mitral regurgitation at discharge and outcomes in patients hospitalized for acute decompensated heart failure with a preserved or reduced ejection fraction. Eur J Heart Fail. 2016; 18(8): 1051–1059.
  8. Cioffi G, Tarantini L, De Feo S, et al. Functional mitral regurgitation predicts 1-year mortality in elderly patients with systolic chronic heart failure. Eur J Heart Fail. 2005; 7(7): 1112–1117.
  9. Bursi F, Enriquez-Sarano M, Nkomo VT, et al. Heart failure and death after myocardial infarction in the community: the emerging role of mitral regurgitation. Circulation. 2005; 111(3): 295–301.
  10. Lancellotti P, Gérard PL, Piérard LA. Long-term outcome of patients with heart failure and dynamic functional mitral regurgitation. Eur Heart J. 2005; 26(15): 1528–1532.
  11. Grande-Allen KJ, Borowski AG, Troughton RW, et al. Apparently normal mitral valves in patients with heart failure demonstrate biochemical and structural derangements: an extracellular matrix and echocardiographic study. J Am Coll Cardiol. 2005; 45(1): 54–61.
  12. Ennezat P, Maréchaux S, Pibarot P, et al. Secondary mitral regurgitation in heart failure with reduced or preserved left ventricular ejection fraction. Cardiology. 2013; 125(2): 110–117.
  13. Aronson D, Goldsher N, Zukermann R, et al. Ischemic mitral regurgitation and risk of heart failure after myocardial infarction. Arch Intern Med. 2006; 166(21): 2362–2368.
  14. Komajda M, Anker SD, Cowie MR, et al. QUALIFY Investigators. Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail. 2016; 18(5): 514–522.
  15. Opolski G, Ozierański K, Lelonek M, et al. The Polish Qualify Investigators. Adherence to the guidelines on the management of systolic heart failure in ambulatory care in Poland. Data from the international QUALIFY survey. Pol Arch Intern Med. 2017; 127(10): 657–665.
  16. Packer M, McMurray JJV, Desai AS, et al. PARADIGM-HF Investigators and Coordinators, PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371(11): 993–1004.
  17. Benjamin MM, Smith RL, Grayburn PA. Ischemic and functional mitral regurgitation in heart failure: natural history and treatment. Curr Cardiol Rep. 2014; 16(8): 517.
  18. Baumgartner H, Falk V, Bax JJ, et al. ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017; 38(36): 2739–2791.
  19. Feldman T, Foster E, Glower D, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011; 364(15): 1395–1406.
  20. Kaplinsky E. Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination. J Geriatr Cardiol. 2016; 13(11): 914–923.
  21. von Lueder TG, Wang BH, Kompa AR, et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail. 2015; 8(1): 71–78.
  22. Iborra-Egea O, Gálvez-Montón C, Roura S, et al. Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach. NPJ Syst Biol Appl. 2017; 3: 12.
  23. Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010; 50(4): 401–414.
  24. Entresto ® — Charakterystyka produktu leczniczego. https://ec.europa.eu/health/documents/community-register/2017/20170111136859/anx_136859_pl.pdf (18.10.2018).
  25. Senni M, McMurray JJV, Wachter R, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 2016; 18(9): 1193–1202.
  26. Chuda A, Lelonek M. Kandydat do nowej terapii niewydolności serca z obniżoną frakcją wyrzutową — ARNI (Angiotensin Receptor-Nephrilysin Inhibitor). Przewodnik klinicysty. Folia Cardiologica. 2016.
  27. Pharmacological Reduction of Functional, Ischemic Mitral Regurgitation (PRIME). https://clinicaltrials.gov/ct2/show/NCT02687932 (18.10.2018).
  28. Lelonek M. The need to apply the best therapy in heart failure — the era after PARADIGM-HF. Arch Med Sci. 2017; 13(5): 1244–1248.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl